Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting
The Pharma Data
DECEMBER 3, 2020
December 5, 2:00 PM – 3:30 PM; Platform A: Translational Research / Genetics. Translational Research / 2B. Antisense Oligonucleotides Increase Scn1a Expression and Reduce Seizures and SUDEP Incidence in a Mouse Model of Dravet Syndrome. .–( BUSINESS WIRE )– Stoke Therapeutics , Inc. Devices, Technologies, Stem Cells.
52 
Let's personalize your content